STUDYID,SUBJID,USUBJID,AGE,STR01,STR01N,STR01L,STR02,STR02N,STR02L,TRT01P,TRT01PN,PARAM,PARAMCD,AVAL,CNSR,CNSDTDSC,DCTREAS
PSIVISSIG0002,1,PSIVISSIG0002_1,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2,PSIVISSIG0002_2,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1101,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,3,PSIVISSIG0002_3,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1771,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,4,PSIVISSIG0002_4,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,289,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,5,PSIVISSIG0002_5,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,6,PSIVISSIG0002_6,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,7,PSIVISSIG0002_7,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,PSIVISSIG0002_8,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,9,PSIVISSIG0002_9,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,10,PSIVISSIG0002_10,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,11,PSIVISSIG0002_11,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,12,PSIVISSIG0002_12,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,13,PSIVISSIG0002_13,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,14,PSIVISSIG0002_14,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1501,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,15,PSIVISSIG0002_15,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,21,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,16,PSIVISSIG0002_16,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,17,PSIVISSIG0002_17,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,124,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,18,PSIVISSIG0002_18,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,560,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,19,PSIVISSIG0002_19,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,20,PSIVISSIG0002_20,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,179,1,Censored at the last contact date,DEATH
PSIVISSIG0002,21,PSIVISSIG0002_21,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,22,PSIVISSIG0002_22,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,23,PSIVISSIG0002_23,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1093,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,24,PSIVISSIG0002_24,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,680,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,25,PSIVISSIG0002_25,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,26,PSIVISSIG0002_26,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,27,PSIVISSIG0002_27,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,28,PSIVISSIG0002_28,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,PSIVISSIG0002_29,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,30,PSIVISSIG0002_30,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,PSIVISSIG0002_31,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,32,PSIVISSIG0002_32,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,33,PSIVISSIG0002_33,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,PSIVISSIG0002_34,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,35,PSIVISSIG0002_35,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,36,PSIVISSIG0002_36,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,37,PSIVISSIG0002_37,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,311,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,PSIVISSIG0002_38,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,39,PSIVISSIG0002_39,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,40,PSIVISSIG0002_40,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,655,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,41,PSIVISSIG0002_41,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,42,PSIVISSIG0002_42,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,213,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,43,PSIVISSIG0002_43,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,111,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,44,PSIVISSIG0002_44,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,45,PSIVISSIG0002_45,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,163,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,46,PSIVISSIG0002_46,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,PSIVISSIG0002_47,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,48,PSIVISSIG0002_48,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,49,PSIVISSIG0002_49,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,491,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,50,PSIVISSIG0002_50,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,51,PSIVISSIG0002_51,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,52,PSIVISSIG0002_52,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,53,PSIVISSIG0002_53,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,54,PSIVISSIG0002_54,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,734,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,55,PSIVISSIG0002_55,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,695,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,PSIVISSIG0002_56,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,985,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,57,PSIVISSIG0002_57,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,58,PSIVISSIG0002_58,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,27,1,Censored at the last contact date,DEATH
PSIVISSIG0002,59,PSIVISSIG0002_59,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,60,PSIVISSIG0002_60,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,61,PSIVISSIG0002_61,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,62,PSIVISSIG0002_62,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,324,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,PSIVISSIG0002_63,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,890,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,64,PSIVISSIG0002_64,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,426,1,Censored at the last contact date,DEATH
PSIVISSIG0002,65,PSIVISSIG0002_65,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,66,PSIVISSIG0002_66,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,PSIVISSIG0002_67,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,140,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,PSIVISSIG0002_68,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,69,PSIVISSIG0002_69,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,70,PSIVISSIG0002_70,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,71,PSIVISSIG0002_71,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,819,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,PSIVISSIG0002_72,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,PSIVISSIG0002_73,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,74,PSIVISSIG0002_74,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,75,PSIVISSIG0002_75,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,76,PSIVISSIG0002_76,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,77,PSIVISSIG0002_77,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,785,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,78,PSIVISSIG0002_78,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,79,PSIVISSIG0002_79,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,80,PSIVISSIG0002_80,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,81,PSIVISSIG0002_81,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,82,PSIVISSIG0002_82,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,83,PSIVISSIG0002_83,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,84,PSIVISSIG0002_84,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1153,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,85,PSIVISSIG0002_85,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,PSIVISSIG0002_86,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1691,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,87,PSIVISSIG0002_87,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,88,PSIVISSIG0002_88,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,731,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,PSIVISSIG0002_89,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,657,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,90,PSIVISSIG0002_90,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,808,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,91,PSIVISSIG0002_91,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,92,PSIVISSIG0002_92,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,71,1,Censored at the last contact date,DEATH
PSIVISSIG0002,93,PSIVISSIG0002_93,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,94,PSIVISSIG0002_94,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,977,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,95,PSIVISSIG0002_95,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,96,PSIVISSIG0002_96,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,97,PSIVISSIG0002_97,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,PSIVISSIG0002_98,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,25,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,99,PSIVISSIG0002_99,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,237,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,100,PSIVISSIG0002_100,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,101,PSIVISSIG0002_101,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,102,PSIVISSIG0002_102,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,103,PSIVISSIG0002_103,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,104,PSIVISSIG0002_104,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1326,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,105,PSIVISSIG0002_105,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1546,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,106,PSIVISSIG0002_106,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,79,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,107,PSIVISSIG0002_107,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,744,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,108,PSIVISSIG0002_108,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1249,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,109,PSIVISSIG0002_109,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,110,PSIVISSIG0002_110,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,111,PSIVISSIG0002_111,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,631,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,112,PSIVISSIG0002_112,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,113,PSIVISSIG0002_113,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,PSIVISSIG0002_114,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,626,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,115,PSIVISSIG0002_115,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,116,PSIVISSIG0002_116,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,274,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,PSIVISSIG0002_117,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,PSIVISSIG0002_118,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1207,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,PSIVISSIG0002_119,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,120,PSIVISSIG0002_120,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,121,PSIVISSIG0002_121,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,PSIVISSIG0002_122,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,123,PSIVISSIG0002_123,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,124,PSIVISSIG0002_124,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,125,PSIVISSIG0002_125,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,304,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,126,PSIVISSIG0002_126,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,127,PSIVISSIG0002_127,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,128,PSIVISSIG0002_128,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,129,PSIVISSIG0002_129,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,PSIVISSIG0002_130,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,779,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,131,PSIVISSIG0002_131,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1050,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,132,PSIVISSIG0002_132,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,639,1,Censored at the last contact date,DEATH
PSIVISSIG0002,133,PSIVISSIG0002_133,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,828,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,134,PSIVISSIG0002_134,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,135,PSIVISSIG0002_135,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,PSIVISSIG0002_136,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,137,PSIVISSIG0002_137,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,PSIVISSIG0002_138,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,139,PSIVISSIG0002_139,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,140,PSIVISSIG0002_140,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,141,PSIVISSIG0002_141,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,PSIVISSIG0002_142,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,143,PSIVISSIG0002_143,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,144,PSIVISSIG0002_144,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,145,PSIVISSIG0002_145,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,618,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,146,PSIVISSIG0002_146,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,72,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,147,PSIVISSIG0002_147,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,148,PSIVISSIG0002_148,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,149,PSIVISSIG0002_149,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,DEATH
PSIVISSIG0002,150,PSIVISSIG0002_150,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,86,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,PSIVISSIG0002_151,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,739,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,152,PSIVISSIG0002_152,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,153,PSIVISSIG0002_153,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,PSIVISSIG0002_154,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1083,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,PSIVISSIG0002_155,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,156,PSIVISSIG0002_156,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,273,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,157,PSIVISSIG0002_157,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,665,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,158,PSIVISSIG0002_158,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,159,PSIVISSIG0002_159,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,970,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,160,PSIVISSIG0002_160,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,PSIVISSIG0002_161,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,PSIVISSIG0002_162,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1053,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,163,PSIVISSIG0002_163,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,PSIVISSIG0002_164,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,165,PSIVISSIG0002_165,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,181,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,166,PSIVISSIG0002_166,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,735,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,167,PSIVISSIG0002_167,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,168,PSIVISSIG0002_168,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,169,PSIVISSIG0002_169,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,170,PSIVISSIG0002_170,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,171,PSIVISSIG0002_171,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,642,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,172,PSIVISSIG0002_172,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,173,PSIVISSIG0002_173,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,120,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,174,PSIVISSIG0002_174,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,175,PSIVISSIG0002_175,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,PSIVISSIG0002_176,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1606,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,177,PSIVISSIG0002_177,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,178,PSIVISSIG0002_178,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,179,PSIVISSIG0002_179,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,180,PSIVISSIG0002_180,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,181,PSIVISSIG0002_181,17,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,PSIVISSIG0002_182,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,183,PSIVISSIG0002_183,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,184,PSIVISSIG0002_184,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1260,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,185,PSIVISSIG0002_185,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,186,PSIVISSIG0002_186,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,929,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,187,PSIVISSIG0002_187,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,188,PSIVISSIG0002_188,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,189,PSIVISSIG0002_189,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,190,PSIVISSIG0002_190,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,191,PSIVISSIG0002_191,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,192,PSIVISSIG0002_192,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,193,PSIVISSIG0002_193,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,194,PSIVISSIG0002_194,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,195,PSIVISSIG0002_195,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,332,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,196,PSIVISSIG0002_196,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,986,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,197,PSIVISSIG0002_197,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,198,PSIVISSIG0002_198,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1623,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,199,PSIVISSIG0002_199,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,930,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,PSIVISSIG0002_200,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,201,PSIVISSIG0002_201,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,PSIVISSIG0002_202,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,203,PSIVISSIG0002_203,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,204,PSIVISSIG0002_204,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,953,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,205,PSIVISSIG0002_205,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,206,PSIVISSIG0002_206,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,PSIVISSIG0002_207,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,548,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,208,PSIVISSIG0002_208,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,209,PSIVISSIG0002_209,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,210,PSIVISSIG0002_210,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,211,PSIVISSIG0002_211,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,212,PSIVISSIG0002_212,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,213,PSIVISSIG0002_213,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,81,1,Censored at the last contact date,DEATH
PSIVISSIG0002,214,PSIVISSIG0002_214,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,215,PSIVISSIG0002_215,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,216,PSIVISSIG0002_216,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,217,PSIVISSIG0002_217,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,218,PSIVISSIG0002_218,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,571,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,219,PSIVISSIG0002_219,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,220,PSIVISSIG0002_220,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,212,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,PSIVISSIG0002_221,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1432,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,222,PSIVISSIG0002_222,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,223,PSIVISSIG0002_223,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,224,PSIVISSIG0002_224,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,225,PSIVISSIG0002_225,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,190,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,226,PSIVISSIG0002_226,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,227,PSIVISSIG0002_227,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,228,PSIVISSIG0002_228,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,229,PSIVISSIG0002_229,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1572,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,PSIVISSIG0002_230,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,769,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,231,PSIVISSIG0002_231,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,232,PSIVISSIG0002_232,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,233,PSIVISSIG0002_233,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,234,PSIVISSIG0002_234,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,235,PSIVISSIG0002_235,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,236,PSIVISSIG0002_236,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,237,PSIVISSIG0002_237,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,238,PSIVISSIG0002_238,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,239,PSIVISSIG0002_239,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,184,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,240,PSIVISSIG0002_240,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,241,PSIVISSIG0002_241,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,242,PSIVISSIG0002_242,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,243,PSIVISSIG0002_243,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,941,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,244,PSIVISSIG0002_244,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,245,PSIVISSIG0002_245,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,246,PSIVISSIG0002_246,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,247,PSIVISSIG0002_247,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,248,PSIVISSIG0002_248,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,249,PSIVISSIG0002_249,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,PSIVISSIG0002_250,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,251,PSIVISSIG0002_251,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,998,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,PSIVISSIG0002_252,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,253,PSIVISSIG0002_253,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1748,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,254,PSIVISSIG0002_254,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,752,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,255,PSIVISSIG0002_255,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,256,PSIVISSIG0002_256,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,257,PSIVISSIG0002_257,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,258,PSIVISSIG0002_258,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,259,PSIVISSIG0002_259,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,260,PSIVISSIG0002_260,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,261,PSIVISSIG0002_261,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,281,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,PSIVISSIG0002_262,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,263,PSIVISSIG0002_263,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,264,PSIVISSIG0002_264,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,PSIVISSIG0002_265,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,266,PSIVISSIG0002_266,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,267,PSIVISSIG0002_267,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,268,PSIVISSIG0002_268,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,269,PSIVISSIG0002_269,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,287,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,PSIVISSIG0002_270,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,271,PSIVISSIG0002_271,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,272,PSIVISSIG0002_272,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,273,PSIVISSIG0002_273,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,PSIVISSIG0002_274,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,275,PSIVISSIG0002_275,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,276,PSIVISSIG0002_276,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,277,PSIVISSIG0002_277,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,278,PSIVISSIG0002_278,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,279,PSIVISSIG0002_279,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,280,PSIVISSIG0002_280,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,Censored at the last contact date,DEATH
PSIVISSIG0002,281,PSIVISSIG0002_281,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,552,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,282,PSIVISSIG0002_282,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,283,PSIVISSIG0002_283,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,284,PSIVISSIG0002_284,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,285,PSIVISSIG0002_285,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,286,PSIVISSIG0002_286,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,287,PSIVISSIG0002_287,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1677,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,288,PSIVISSIG0002_288,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,289,PSIVISSIG0002_289,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,290,PSIVISSIG0002_290,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1488,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,291,PSIVISSIG0002_291,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,621,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,292,PSIVISSIG0002_292,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,293,PSIVISSIG0002_293,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,294,PSIVISSIG0002_294,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,295,PSIVISSIG0002_295,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,296,PSIVISSIG0002_296,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,297,PSIVISSIG0002_297,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,402,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,298,PSIVISSIG0002_298,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,275,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,299,PSIVISSIG0002_299,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,300,PSIVISSIG0002_300,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,301,PSIVISSIG0002_301,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,302,PSIVISSIG0002_302,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,303,PSIVISSIG0002_303,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1644,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,304,PSIVISSIG0002_304,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,882,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,305,PSIVISSIG0002_305,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,306,PSIVISSIG0002_306,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,763,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,PSIVISSIG0002_307,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,PSIVISSIG0002_308,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,309,PSIVISSIG0002_309,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,310,PSIVISSIG0002_310,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,311,PSIVISSIG0002_311,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,102,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,312,PSIVISSIG0002_312,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,313,PSIVISSIG0002_313,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,153,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,314,PSIVISSIG0002_314,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,315,PSIVISSIG0002_315,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,316,PSIVISSIG0002_316,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,PSIVISSIG0002_317,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,811,1,Censored at the last contact date,DEATH
PSIVISSIG0002,318,PSIVISSIG0002_318,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,319,PSIVISSIG0002_319,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,320,PSIVISSIG0002_320,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,321,PSIVISSIG0002_321,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,322,PSIVISSIG0002_322,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,323,PSIVISSIG0002_323,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,324,PSIVISSIG0002_324,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,325,PSIVISSIG0002_325,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,326,PSIVISSIG0002_326,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,PSIVISSIG0002_327,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,801,1,Censored at the last contact date,DEATH
PSIVISSIG0002,328,PSIVISSIG0002_328,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,329,PSIVISSIG0002_329,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,330,PSIVISSIG0002_330,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,331,PSIVISSIG0002_331,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,332,PSIVISSIG0002_332,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,333,PSIVISSIG0002_333,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,334,PSIVISSIG0002_334,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,335,PSIVISSIG0002_335,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,PSIVISSIG0002_336,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,5,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,337,PSIVISSIG0002_337,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,338,PSIVISSIG0002_338,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,794,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,339,PSIVISSIG0002_339,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1089,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,PSIVISSIG0002_340,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,341,PSIVISSIG0002_341,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,480,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,342,PSIVISSIG0002_342,63,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,343,PSIVISSIG0002_343,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,601,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,344,PSIVISSIG0002_344,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,345,PSIVISSIG0002_345,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,346,PSIVISSIG0002_346,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,PSIVISSIG0002_347,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,348,PSIVISSIG0002_348,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,349,PSIVISSIG0002_349,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,350,PSIVISSIG0002_350,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,825,1,Censored at the last contact date,DEATH
PSIVISSIG0002,351,PSIVISSIG0002_351,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,352,PSIVISSIG0002_352,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,353,PSIVISSIG0002_353,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,354,PSIVISSIG0002_354,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,355,PSIVISSIG0002_355,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,356,PSIVISSIG0002_356,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,229,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,357,PSIVISSIG0002_357,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,345,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,358,PSIVISSIG0002_358,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,359,PSIVISSIG0002_359,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,368,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,360,PSIVISSIG0002_360,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1025,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,361,PSIVISSIG0002_361,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,766,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,362,PSIVISSIG0002_362,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,363,PSIVISSIG0002_363,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,364,PSIVISSIG0002_364,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,365,PSIVISSIG0002_365,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,366,PSIVISSIG0002_366,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,367,PSIVISSIG0002_367,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,250,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,368,PSIVISSIG0002_368,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,30,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,369,PSIVISSIG0002_369,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,370,PSIVISSIG0002_370,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,371,PSIVISSIG0002_371,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,372,PSIVISSIG0002_372,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,178,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,373,PSIVISSIG0002_373,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,374,PSIVISSIG0002_374,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,PSIVISSIG0002_375,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,171,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,376,PSIVISSIG0002_376,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,377,PSIVISSIG0002_377,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,PSIVISSIG0002_378,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,21,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,379,PSIVISSIG0002_379,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,380,PSIVISSIG0002_380,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,381,PSIVISSIG0002_381,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,755,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,382,PSIVISSIG0002_382,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,383,PSIVISSIG0002_383,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,384,PSIVISSIG0002_384,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,PSIVISSIG0002_385,26,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,386,PSIVISSIG0002_386,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,387,PSIVISSIG0002_387,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,136,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,388,PSIVISSIG0002_388,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,711,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,389,PSIVISSIG0002_389,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,390,PSIVISSIG0002_390,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,572,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,391,PSIVISSIG0002_391,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,392,PSIVISSIG0002_392,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1247,1,Censored at the last contact date,DEATH
PSIVISSIG0002,393,PSIVISSIG0002_393,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,394,PSIVISSIG0002_394,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,11,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,395,PSIVISSIG0002_395,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,396,PSIVISSIG0002_396,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,PSIVISSIG0002_397,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,398,PSIVISSIG0002_398,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,399,PSIVISSIG0002_399,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,400,PSIVISSIG0002_400,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,512,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,401,PSIVISSIG0002_401,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,402,PSIVISSIG0002_402,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,524,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,403,PSIVISSIG0002_403,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,70,1,Censored at the last contact date,DEATH
PSIVISSIG0002,404,PSIVISSIG0002_404,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,405,PSIVISSIG0002_405,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,406,PSIVISSIG0002_406,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,407,PSIVISSIG0002_407,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,408,PSIVISSIG0002_408,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,698,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,PSIVISSIG0002_409,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,410,PSIVISSIG0002_410,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,411,PSIVISSIG0002_411,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,412,PSIVISSIG0002_412,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,413,PSIVISSIG0002_413,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,414,PSIVISSIG0002_414,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,415,PSIVISSIG0002_415,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,416,PSIVISSIG0002_416,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,888,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,417,PSIVISSIG0002_417,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,DEATH
PSIVISSIG0002,418,PSIVISSIG0002_418,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,419,PSIVISSIG0002_419,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,420,PSIVISSIG0002_420,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,421,PSIVISSIG0002_421,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,422,PSIVISSIG0002_422,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,423,PSIVISSIG0002_423,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,424,PSIVISSIG0002_424,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,425,PSIVISSIG0002_425,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,426,PSIVISSIG0002_426,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,427,PSIVISSIG0002_427,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,428,PSIVISSIG0002_428,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,429,PSIVISSIG0002_429,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,226,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,PSIVISSIG0002_430,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,934,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,PSIVISSIG0002_431,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,432,PSIVISSIG0002_432,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,433,PSIVISSIG0002_433,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,471,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,434,PSIVISSIG0002_434,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,834,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,435,PSIVISSIG0002_435,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,436,PSIVISSIG0002_436,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,437,PSIVISSIG0002_437,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,438,PSIVISSIG0002_438,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,243,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,439,PSIVISSIG0002_439,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,639,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,440,PSIVISSIG0002_440,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,176,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,441,PSIVISSIG0002_441,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,442,PSIVISSIG0002_442,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,443,PSIVISSIG0002_443,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,703,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,444,PSIVISSIG0002_444,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,445,PSIVISSIG0002_445,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,PSIVISSIG0002_446,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,447,PSIVISSIG0002_447,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1046,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,448,PSIVISSIG0002_448,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,489,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,449,PSIVISSIG0002_449,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,450,PSIVISSIG0002_450,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,451,PSIVISSIG0002_451,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,452,PSIVISSIG0002_452,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,536,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,453,PSIVISSIG0002_453,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,PSIVISSIG0002_454,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,455,PSIVISSIG0002_455,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,100,1,Censored at the last contact date,DEATH
PSIVISSIG0002,456,PSIVISSIG0002_456,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,457,PSIVISSIG0002_457,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,458,PSIVISSIG0002_458,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,459,PSIVISSIG0002_459,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,460,PSIVISSIG0002_460,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,384,1,Censored at the last contact date,DEATH
PSIVISSIG0002,461,PSIVISSIG0002_461,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,462,PSIVISSIG0002_462,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,463,PSIVISSIG0002_463,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,DEATH
PSIVISSIG0002,464,PSIVISSIG0002_464,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,465,PSIVISSIG0002_465,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,409,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,466,PSIVISSIG0002_466,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,467,PSIVISSIG0002_467,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,468,PSIVISSIG0002_468,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,253,1,Censored at the last contact date,DEATH
PSIVISSIG0002,469,PSIVISSIG0002_469,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,470,PSIVISSIG0002_470,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,471,PSIVISSIG0002_471,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,PSIVISSIG0002_472,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,473,PSIVISSIG0002_473,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,167,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,474,PSIVISSIG0002_474,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1465,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,PSIVISSIG0002_475,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,476,PSIVISSIG0002_476,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1710,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,477,PSIVISSIG0002_477,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1664,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,478,PSIVISSIG0002_478,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,479,PSIVISSIG0002_479,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,480,PSIVISSIG0002_480,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,22,1,Censored at the last contact date,DEATH
PSIVISSIG0002,481,PSIVISSIG0002_481,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,PSIVISSIG0002_482,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,119,1,Censored at the last contact date,DEATH
PSIVISSIG0002,483,PSIVISSIG0002_483,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,51,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,484,PSIVISSIG0002_484,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,729,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,485,PSIVISSIG0002_485,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,486,PSIVISSIG0002_486,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,487,PSIVISSIG0002_487,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,488,PSIVISSIG0002_488,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,489,PSIVISSIG0002_489,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1098,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,PSIVISSIG0002_490,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,491,PSIVISSIG0002_491,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,492,PSIVISSIG0002_492,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,493,PSIVISSIG0002_493,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,494,PSIVISSIG0002_494,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,495,PSIVISSIG0002_495,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,496,PSIVISSIG0002_496,19,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,497,PSIVISSIG0002_497,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,498,PSIVISSIG0002_498,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,499,PSIVISSIG0002_499,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1030,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,500,PSIVISSIG0002_500,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,501,PSIVISSIG0002_501,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,502,PSIVISSIG0002_502,13,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,PSIVISSIG0002_503,28,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,504,PSIVISSIG0002_504,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,505,PSIVISSIG0002_505,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,506,PSIVISSIG0002_506,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,590,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,507,PSIVISSIG0002_507,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,508,PSIVISSIG0002_508,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1078,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,509,PSIVISSIG0002_509,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,510,PSIVISSIG0002_510,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,511,PSIVISSIG0002_511,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,512,PSIVISSIG0002_512,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,513,PSIVISSIG0002_513,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,514,PSIVISSIG0002_514,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,515,PSIVISSIG0002_515,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,PSIVISSIG0002_516,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,517,PSIVISSIG0002_517,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,518,PSIVISSIG0002_518,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,PSIVISSIG0002_519,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,971,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,520,PSIVISSIG0002_520,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1760,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,521,PSIVISSIG0002_521,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,522,PSIVISSIG0002_522,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,903,1,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,523,PSIVISSIG0002_523,19,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,524,PSIVISSIG0002_524,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,525,PSIVISSIG0002_525,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,526,PSIVISSIG0002_526,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,527,PSIVISSIG0002_527,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,528,PSIVISSIG0002_528,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,529,PSIVISSIG0002_529,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,530,PSIVISSIG0002_530,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1071,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,531,PSIVISSIG0002_531,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,PSIVISSIG0002_532,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,533,PSIVISSIG0002_533,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,534,PSIVISSIG0002_534,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,535,PSIVISSIG0002_535,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,536,PSIVISSIG0002_536,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,537,PSIVISSIG0002_537,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,538,PSIVISSIG0002_538,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,539,PSIVISSIG0002_539,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,PSIVISSIG0002_540,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,455,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,541,PSIVISSIG0002_541,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,542,PSIVISSIG0002_542,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,543,PSIVISSIG0002_543,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,544,PSIVISSIG0002_544,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,545,PSIVISSIG0002_545,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,546,PSIVISSIG0002_546,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,547,PSIVISSIG0002_547,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,548,PSIVISSIG0002_548,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,779,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,549,PSIVISSIG0002_549,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,550,PSIVISSIG0002_550,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,551,PSIVISSIG0002_551,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,544,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,552,PSIVISSIG0002_552,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,553,PSIVISSIG0002_553,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,PSIVISSIG0002_554,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,555,PSIVISSIG0002_555,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,857,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,556,PSIVISSIG0002_556,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,3,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,557,PSIVISSIG0002_557,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,558,PSIVISSIG0002_558,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,559,PSIVISSIG0002_559,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,560,PSIVISSIG0002_560,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,17,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,561,PSIVISSIG0002_561,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,922,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,PSIVISSIG0002_562,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,563,PSIVISSIG0002_563,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,DEATH
PSIVISSIG0002,564,PSIVISSIG0002_564,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,565,PSIVISSIG0002_565,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,566,PSIVISSIG0002_566,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,567,PSIVISSIG0002_567,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,PSIVISSIG0002_568,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,569,PSIVISSIG0002_569,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,570,PSIVISSIG0002_570,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,PSIVISSIG0002_571,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,572,PSIVISSIG0002_572,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,4,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,573,PSIVISSIG0002_573,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,574,PSIVISSIG0002_574,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,575,PSIVISSIG0002_575,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,576,PSIVISSIG0002_576,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,53,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,PSIVISSIG0002_577,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,578,PSIVISSIG0002_578,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,PSIVISSIG0002_579,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,580,PSIVISSIG0002_580,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,581,PSIVISSIG0002_581,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,582,PSIVISSIG0002_582,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,583,PSIVISSIG0002_583,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,584,PSIVISSIG0002_584,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,PSIVISSIG0002_585,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,586,PSIVISSIG0002_586,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,587,PSIVISSIG0002_587,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,588,PSIVISSIG0002_588,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,589,PSIVISSIG0002_589,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,590,PSIVISSIG0002_590,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,PSIVISSIG0002_591,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,592,PSIVISSIG0002_592,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,859,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,593,PSIVISSIG0002_593,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,594,PSIVISSIG0002_594,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1667,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,PSIVISSIG0002_595,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,DEATH
PSIVISSIG0002,596,PSIVISSIG0002_596,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,597,PSIVISSIG0002_597,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,414,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,598,PSIVISSIG0002_598,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,599,PSIVISSIG0002_599,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,958,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,600,PSIVISSIG0002_600,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,601,PSIVISSIG0002_601,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,602,PSIVISSIG0002_602,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,603,PSIVISSIG0002_603,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,955,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,604,PSIVISSIG0002_604,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,605,PSIVISSIG0002_605,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,606,PSIVISSIG0002_606,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1226,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,607,PSIVISSIG0002_607,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,719,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,PSIVISSIG0002_608,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,222,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,609,PSIVISSIG0002_609,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,610,PSIVISSIG0002_610,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,611,PSIVISSIG0002_611,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,DEATH
PSIVISSIG0002,612,PSIVISSIG0002_612,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1286,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,613,PSIVISSIG0002_613,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,175,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,614,PSIVISSIG0002_614,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,615,PSIVISSIG0002_615,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,616,PSIVISSIG0002_616,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,854,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,PSIVISSIG0002_617,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,618,PSIVISSIG0002_618,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,619,PSIVISSIG0002_619,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,799,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,620,PSIVISSIG0002_620,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,164,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,621,PSIVISSIG0002_621,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,622,PSIVISSIG0002_622,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,983,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,PSIVISSIG0002_623,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,646,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,624,PSIVISSIG0002_624,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,625,PSIVISSIG0002_625,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,626,PSIVISSIG0002_626,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,627,PSIVISSIG0002_627,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,261,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,628,PSIVISSIG0002_628,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,629,PSIVISSIG0002_629,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,630,PSIVISSIG0002_630,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,631,PSIVISSIG0002_631,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,6,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,632,PSIVISSIG0002_632,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,633,PSIVISSIG0002_633,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1532,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,634,PSIVISSIG0002_634,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,635,PSIVISSIG0002_635,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,636,PSIVISSIG0002_636,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,637,PSIVISSIG0002_637,25,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,638,PSIVISSIG0002_638,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,366,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,639,PSIVISSIG0002_639,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,640,PSIVISSIG0002_640,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,PSIVISSIG0002_641,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,642,PSIVISSIG0002_642,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,578,1,Censored at the last contact date,DEATH
PSIVISSIG0002,643,PSIVISSIG0002_643,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,298,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,644,PSIVISSIG0002_644,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,37,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,645,PSIVISSIG0002_645,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,646,PSIVISSIG0002_646,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,647,PSIVISSIG0002_647,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,648,PSIVISSIG0002_648,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,649,PSIVISSIG0002_649,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,650,PSIVISSIG0002_650,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,651,PSIVISSIG0002_651,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,PSIVISSIG0002_652,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,825,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,653,PSIVISSIG0002_653,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,654,PSIVISSIG0002_654,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1588,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,655,PSIVISSIG0002_655,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,989,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,656,PSIVISSIG0002_656,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,PSIVISSIG0002_657,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,987,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,658,PSIVISSIG0002_658,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,PSIVISSIG0002_659,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,660,PSIVISSIG0002_660,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,661,PSIVISSIG0002_661,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,662,PSIVISSIG0002_662,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,663,PSIVISSIG0002_663,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,664,PSIVISSIG0002_664,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,705,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,665,PSIVISSIG0002_665,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,666,PSIVISSIG0002_666,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,667,PSIVISSIG0002_667,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,668,PSIVISSIG0002_668,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,669,PSIVISSIG0002_669,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1293,1,Censored at the last contact date,DEATH
PSIVISSIG0002,670,PSIVISSIG0002_670,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,802,1,Censored at the last contact date,DEATH
PSIVISSIG0002,671,PSIVISSIG0002_671,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,672,PSIVISSIG0002_672,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,673,PSIVISSIG0002_673,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1647,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,674,PSIVISSIG0002_674,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,675,PSIVISSIG0002_675,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,DEATH
PSIVISSIG0002,676,PSIVISSIG0002_676,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,677,PSIVISSIG0002_677,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,678,PSIVISSIG0002_678,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,679,PSIVISSIG0002_679,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,123,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,680,PSIVISSIG0002_680,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,681,PSIVISSIG0002_681,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,682,PSIVISSIG0002_682,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,683,PSIVISSIG0002_683,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,684,PSIVISSIG0002_684,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1011,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,685,PSIVISSIG0002_685,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,686,PSIVISSIG0002_686,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1124,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,PSIVISSIG0002_687,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,688,PSIVISSIG0002_688,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,689,PSIVISSIG0002_689,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,690,PSIVISSIG0002_690,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,691,PSIVISSIG0002_691,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1072,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,PSIVISSIG0002_692,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,PSIVISSIG0002_693,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,694,PSIVISSIG0002_694,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,695,PSIVISSIG0002_695,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,696,PSIVISSIG0002_696,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,Censored at the last contact date,DEATH
PSIVISSIG0002,697,PSIVISSIG0002_697,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,234,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,698,PSIVISSIG0002_698,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1426,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,699,PSIVISSIG0002_699,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,310,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,700,PSIVISSIG0002_700,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,206,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,701,PSIVISSIG0002_701,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,DEATH
PSIVISSIG0002,702,PSIVISSIG0002_702,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,703,PSIVISSIG0002_703,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,479,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,704,PSIVISSIG0002_704,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1651,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,705,PSIVISSIG0002_705,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,PSIVISSIG0002_706,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1529,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,707,PSIVISSIG0002_707,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,708,PSIVISSIG0002_708,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,94,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,709,PSIVISSIG0002_709,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1461,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,710,PSIVISSIG0002_710,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,PSIVISSIG0002_711,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1452,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,712,PSIVISSIG0002_712,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,713,PSIVISSIG0002_713,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,714,PSIVISSIG0002_714,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,715,PSIVISSIG0002_715,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,716,PSIVISSIG0002_716,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,717,PSIVISSIG0002_717,25,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,718,PSIVISSIG0002_718,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,877,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,719,PSIVISSIG0002_719,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,481,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,PSIVISSIG0002_720,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,721,PSIVISSIG0002_721,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,722,PSIVISSIG0002_722,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,723,PSIVISSIG0002_723,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,PSIVISSIG0002_724,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,824,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,725,PSIVISSIG0002_725,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,PSIVISSIG0002_726,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,727,PSIVISSIG0002_727,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,PSIVISSIG0002_728,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1683,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,729,PSIVISSIG0002_729,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,730,PSIVISSIG0002_730,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,731,PSIVISSIG0002_731,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,PSIVISSIG0002_732,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,733,PSIVISSIG0002_733,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,734,PSIVISSIG0002_734,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,735,PSIVISSIG0002_735,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1256,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,736,PSIVISSIG0002_736,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,737,PSIVISSIG0002_737,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,738,PSIVISSIG0002_738,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,739,PSIVISSIG0002_739,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,740,PSIVISSIG0002_740,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,741,PSIVISSIG0002_741,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,742,PSIVISSIG0002_742,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,743,PSIVISSIG0002_743,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,744,PSIVISSIG0002_744,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,745,PSIVISSIG0002_745,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,654,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,PSIVISSIG0002_746,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,747,PSIVISSIG0002_747,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,390,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,748,PSIVISSIG0002_748,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,749,PSIVISSIG0002_749,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,449,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,750,PSIVISSIG0002_750,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,751,PSIVISSIG0002_751,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,752,PSIVISSIG0002_752,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,753,PSIVISSIG0002_753,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,PSIVISSIG0002_754,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,PSIVISSIG0002_755,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,756,PSIVISSIG0002_756,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,757,PSIVISSIG0002_757,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,758,PSIVISSIG0002_758,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,759,PSIVISSIG0002_759,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,931,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,760,PSIVISSIG0002_760,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,247,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,PSIVISSIG0002_761,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,PSIVISSIG0002_762,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,763,PSIVISSIG0002_763,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,764,PSIVISSIG0002_764,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,765,PSIVISSIG0002_765,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,766,PSIVISSIG0002_766,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,767,PSIVISSIG0002_767,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,768,PSIVISSIG0002_768,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,769,PSIVISSIG0002_769,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,809,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,770,PSIVISSIG0002_770,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,771,PSIVISSIG0002_771,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,772,PSIVISSIG0002_772,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,7,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,773,PSIVISSIG0002_773,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,774,PSIVISSIG0002_774,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,433,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,775,PSIVISSIG0002_775,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,776,PSIVISSIG0002_776,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,777,PSIVISSIG0002_777,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,778,PSIVISSIG0002_778,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,779,PSIVISSIG0002_779,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,DEATH
PSIVISSIG0002,780,PSIVISSIG0002_780,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,781,PSIVISSIG0002_781,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,782,PSIVISSIG0002_782,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,783,PSIVISSIG0002_783,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,754,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,784,PSIVISSIG0002_784,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,932,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,785,PSIVISSIG0002_785,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,946,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,786,PSIVISSIG0002_786,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1008,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,787,PSIVISSIG0002_787,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,788,PSIVISSIG0002_788,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,789,PSIVISSIG0002_789,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,790,PSIVISSIG0002_790,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,791,PSIVISSIG0002_791,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,792,PSIVISSIG0002_792,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,793,PSIVISSIG0002_793,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,794,PSIVISSIG0002_794,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,795,PSIVISSIG0002_795,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1542,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,796,PSIVISSIG0002_796,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,797,PSIVISSIG0002_797,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1696,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,798,PSIVISSIG0002_798,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,799,PSIVISSIG0002_799,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,800,PSIVISSIG0002_800,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,801,PSIVISSIG0002_801,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,2,1,Censored at the last contact date,DEATH
PSIVISSIG0002,802,PSIVISSIG0002_802,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,803,PSIVISSIG0002_803,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,804,PSIVISSIG0002_804,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,805,PSIVISSIG0002_805,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,806,PSIVISSIG0002_806,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,807,PSIVISSIG0002_807,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,808,PSIVISSIG0002_808,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,809,PSIVISSIG0002_809,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,837,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,810,PSIVISSIG0002_810,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,811,PSIVISSIG0002_811,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,PSIVISSIG0002_812,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,813,PSIVISSIG0002_813,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,757,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,PSIVISSIG0002_814,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,815,PSIVISSIG0002_815,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1596,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,816,PSIVISSIG0002_816,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,817,PSIVISSIG0002_817,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,818,PSIVISSIG0002_818,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,876,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,819,PSIVISSIG0002_819,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,820,PSIVISSIG0002_820,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,821,PSIVISSIG0002_821,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,822,PSIVISSIG0002_822,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,823,PSIVISSIG0002_823,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,PSIVISSIG0002_824,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,661,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,825,PSIVISSIG0002_825,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,PSIVISSIG0002_826,30,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,827,PSIVISSIG0002_827,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,828,PSIVISSIG0002_828,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,829,PSIVISSIG0002_829,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,373,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,830,PSIVISSIG0002_830,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,831,PSIVISSIG0002_831,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,832,PSIVISSIG0002_832,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1629,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,833,PSIVISSIG0002_833,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,834,PSIVISSIG0002_834,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,835,PSIVISSIG0002_835,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,836,PSIVISSIG0002_836,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,PSIVISSIG0002_837,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,180,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,PSIVISSIG0002_838,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,839,PSIVISSIG0002_839,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,840,PSIVISSIG0002_840,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,841,PSIVISSIG0002_841,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,842,PSIVISSIG0002_842,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,843,PSIVISSIG0002_843,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,844,PSIVISSIG0002_844,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,845,PSIVISSIG0002_845,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,846,PSIVISSIG0002_846,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,847,PSIVISSIG0002_847,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,848,PSIVISSIG0002_848,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,849,PSIVISSIG0002_849,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,850,PSIVISSIG0002_850,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,851,PSIVISSIG0002_851,25,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,586,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,852,PSIVISSIG0002_852,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1418,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,PSIVISSIG0002_853,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,PSIVISSIG0002_854,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,855,PSIVISSIG0002_855,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,856,PSIVISSIG0002_856,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1208,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,857,PSIVISSIG0002_857,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,858,PSIVISSIG0002_858,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,993,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,859,PSIVISSIG0002_859,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,PSIVISSIG0002_860,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,861,PSIVISSIG0002_861,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,862,PSIVISSIG0002_862,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,863,PSIVISSIG0002_863,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,551,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,864,PSIVISSIG0002_864,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,PSIVISSIG0002_865,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,PSIVISSIG0002_866,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,PSIVISSIG0002_867,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,868,PSIVISSIG0002_868,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,705,1,Censored at the last contact date,DEATH
PSIVISSIG0002,869,PSIVISSIG0002_869,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,870,PSIVISSIG0002_870,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,871,PSIVISSIG0002_871,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1353,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,872,PSIVISSIG0002_872,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,873,PSIVISSIG0002_873,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,874,PSIVISSIG0002_874,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,154,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,875,PSIVISSIG0002_875,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,876,PSIVISSIG0002_876,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,877,PSIVISSIG0002_877,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,878,PSIVISSIG0002_878,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,913,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,PSIVISSIG0002_879,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,880,PSIVISSIG0002_880,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,881,PSIVISSIG0002_881,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,528,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,PSIVISSIG0002_882,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,165,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,883,PSIVISSIG0002_883,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,884,PSIVISSIG0002_884,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,885,PSIVISSIG0002_885,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,886,PSIVISSIG0002_886,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,887,PSIVISSIG0002_887,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,888,PSIVISSIG0002_888,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,280,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,889,PSIVISSIG0002_889,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,890,PSIVISSIG0002_890,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,PSIVISSIG0002_891,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,892,PSIVISSIG0002_892,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,893,PSIVISSIG0002_893,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,894,PSIVISSIG0002_894,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,372,1,Censored at the last contact date,DEATH
PSIVISSIG0002,895,PSIVISSIG0002_895,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,896,PSIVISSIG0002_896,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,897,PSIVISSIG0002_897,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,898,PSIVISSIG0002_898,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,899,PSIVISSIG0002_899,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,900,PSIVISSIG0002_900,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,901,PSIVISSIG0002_901,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,218,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,902,PSIVISSIG0002_902,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,903,PSIVISSIG0002_903,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,904,PSIVISSIG0002_904,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,PSIVISSIG0002_905,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,906,PSIVISSIG0002_906,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1075,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,907,PSIVISSIG0002_907,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,PSIVISSIG0002_908,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,90,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,909,PSIVISSIG0002_909,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,910,PSIVISSIG0002_910,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,918,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,911,PSIVISSIG0002_911,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,912,PSIVISSIG0002_912,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,PSIVISSIG0002_913,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,914,PSIVISSIG0002_914,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,PSIVISSIG0002_915,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,916,PSIVISSIG0002_916,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,558,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,917,PSIVISSIG0002_917,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,918,PSIVISSIG0002_918,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,919,PSIVISSIG0002_919,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,23,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,920,PSIVISSIG0002_920,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,921,PSIVISSIG0002_921,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,922,PSIVISSIG0002_922,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,964,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,923,PSIVISSIG0002_923,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,924,PSIVISSIG0002_924,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,925,PSIVISSIG0002_925,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,841,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,926,PSIVISSIG0002_926,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,927,PSIVISSIG0002_927,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,928,PSIVISSIG0002_928,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,929,PSIVISSIG0002_929,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,930,PSIVISSIG0002_930,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,931,PSIVISSIG0002_931,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,932,PSIVISSIG0002_932,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1703,1,Censored at the last contact date,DEATH
PSIVISSIG0002,933,PSIVISSIG0002_933,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1185,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,934,PSIVISSIG0002_934,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1287,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,935,PSIVISSIG0002_935,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,936,PSIVISSIG0002_936,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1513,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,937,PSIVISSIG0002_937,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1712,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,938,PSIVISSIG0002_938,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,939,PSIVISSIG0002_939,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,940,PSIVISSIG0002_940,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,95,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,941,PSIVISSIG0002_941,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,942,PSIVISSIG0002_942,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1514,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,PSIVISSIG0002_943,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,944,PSIVISSIG0002_944,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,945,PSIVISSIG0002_945,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,946,PSIVISSIG0002_946,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,947,PSIVISSIG0002_947,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,948,PSIVISSIG0002_948,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,219,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,949,PSIVISSIG0002_949,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,950,PSIVISSIG0002_950,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,951,PSIVISSIG0002_951,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,952,PSIVISSIG0002_952,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,953,PSIVISSIG0002_953,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,PSIVISSIG0002_954,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,955,PSIVISSIG0002_955,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,956,PSIVISSIG0002_956,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,359,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,PSIVISSIG0002_957,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,958,PSIVISSIG0002_958,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,71,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,959,PSIVISSIG0002_959,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,960,PSIVISSIG0002_960,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,961,PSIVISSIG0002_961,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,962,PSIVISSIG0002_962,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,963,PSIVISSIG0002_963,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,938,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,PSIVISSIG0002_964,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,965,PSIVISSIG0002_965,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,PSIVISSIG0002_966,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,967,PSIVISSIG0002_967,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,PSIVISSIG0002_968,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,404,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,PSIVISSIG0002_969,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,970,PSIVISSIG0002_970,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,971,PSIVISSIG0002_971,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,972,PSIVISSIG0002_972,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,973,PSIVISSIG0002_973,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,944,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,974,PSIVISSIG0002_974,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,975,PSIVISSIG0002_975,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,976,PSIVISSIG0002_976,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,DEATH
PSIVISSIG0002,977,PSIVISSIG0002_977,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,PSIVISSIG0002_978,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1373,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,979,PSIVISSIG0002_979,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,980,PSIVISSIG0002_980,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,981,PSIVISSIG0002_981,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1032,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,982,PSIVISSIG0002_982,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,983,PSIVISSIG0002_983,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,984,PSIVISSIG0002_984,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,985,PSIVISSIG0002_985,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,986,PSIVISSIG0002_986,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,716,1,Censored at the last contact date,DEATH
PSIVISSIG0002,987,PSIVISSIG0002_987,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,988,PSIVISSIG0002_988,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,133,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,989,PSIVISSIG0002_989,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,990,PSIVISSIG0002_990,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,991,PSIVISSIG0002_991,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,PSIVISSIG0002_992,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,867,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,993,PSIVISSIG0002_993,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,994,PSIVISSIG0002_994,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,995,PSIVISSIG0002_995,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,996,PSIVISSIG0002_996,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,352,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,997,PSIVISSIG0002_997,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1374,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,PSIVISSIG0002_998,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,999,PSIVISSIG0002_999,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1000,PSIVISSIG0002_1000,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,PSIVISSIG0002_1001,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1002,PSIVISSIG0002_1002,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,170,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,PSIVISSIG0002_1003,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1004,PSIVISSIG0002_1004,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1005,PSIVISSIG0002_1005,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1006,PSIVISSIG0002_1006,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,9,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1007,PSIVISSIG0002_1007,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1008,PSIVISSIG0002_1008,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,66,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1009,PSIVISSIG0002_1009,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1010,PSIVISSIG0002_1010,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,PSIVISSIG0002_1011,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1012,PSIVISSIG0002_1012,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,918,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1,PSIVISSIG0002_1,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,236,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2,PSIVISSIG0002_2,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,3,PSIVISSIG0002_3,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1126,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,4,PSIVISSIG0002_4,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,410,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,5,PSIVISSIG0002_5,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,6,PSIVISSIG0002_6,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,7,PSIVISSIG0002_7,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,PSIVISSIG0002_8,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1005,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,9,PSIVISSIG0002_9,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,561,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,10,PSIVISSIG0002_10,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1718,1,Censored at the last contact date,DEATH
PSIVISSIG0002,11,PSIVISSIG0002_11,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,12,PSIVISSIG0002_12,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,13,PSIVISSIG0002_13,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,14,PSIVISSIG0002_14,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,880,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,15,PSIVISSIG0002_15,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,628,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,16,PSIVISSIG0002_16,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,17,PSIVISSIG0002_17,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,18,PSIVISSIG0002_18,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,19,PSIVISSIG0002_19,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,417,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,20,PSIVISSIG0002_20,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,21,PSIVISSIG0002_21,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,22,PSIVISSIG0002_22,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,23,PSIVISSIG0002_23,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,24,PSIVISSIG0002_24,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,958,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,25,PSIVISSIG0002_25,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,26,PSIVISSIG0002_26,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,384,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,27,PSIVISSIG0002_27,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,505,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,28,PSIVISSIG0002_28,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,PSIVISSIG0002_29,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,30,PSIVISSIG0002_30,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,PSIVISSIG0002_31,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,32,PSIVISSIG0002_32,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,33,PSIVISSIG0002_33,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,PSIVISSIG0002_34,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,866,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,35,PSIVISSIG0002_35,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,36,PSIVISSIG0002_36,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1238,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,37,PSIVISSIG0002_37,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,PSIVISSIG0002_38,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,39,PSIVISSIG0002_39,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,40,PSIVISSIG0002_40,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,556,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,41,PSIVISSIG0002_41,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,42,PSIVISSIG0002_42,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,206,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,43,PSIVISSIG0002_43,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,44,PSIVISSIG0002_44,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,45,PSIVISSIG0002_45,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,46,PSIVISSIG0002_46,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,9,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,PSIVISSIG0002_47,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,48,PSIVISSIG0002_48,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,49,PSIVISSIG0002_49,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,242,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,50,PSIVISSIG0002_50,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,51,PSIVISSIG0002_51,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,52,PSIVISSIG0002_52,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,53,PSIVISSIG0002_53,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,792,1,Censored at the last contact date,DEATH
PSIVISSIG0002,54,PSIVISSIG0002_54,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,55,PSIVISSIG0002_55,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1014,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,PSIVISSIG0002_56,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,385,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,57,PSIVISSIG0002_57,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1057,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,58,PSIVISSIG0002_58,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,59,PSIVISSIG0002_59,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,DEATH
PSIVISSIG0002,60,PSIVISSIG0002_60,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,265,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,61,PSIVISSIG0002_61,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,62,PSIVISSIG0002_62,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,PSIVISSIG0002_63,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,123,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,64,PSIVISSIG0002_64,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,65,PSIVISSIG0002_65,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,66,PSIVISSIG0002_66,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1564,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,PSIVISSIG0002_67,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,PSIVISSIG0002_68,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,69,PSIVISSIG0002_69,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,70,PSIVISSIG0002_70,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,198,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,71,PSIVISSIG0002_71,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1550,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,PSIVISSIG0002_72,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,PSIVISSIG0002_73,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,74,PSIVISSIG0002_74,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,75,PSIVISSIG0002_75,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,76,PSIVISSIG0002_76,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,77,PSIVISSIG0002_77,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,78,PSIVISSIG0002_78,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,79,PSIVISSIG0002_79,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,80,PSIVISSIG0002_80,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1505,1,Censored at the last contact date,DEATH
PSIVISSIG0002,81,PSIVISSIG0002_81,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,82,PSIVISSIG0002_82,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1457,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,83,PSIVISSIG0002_83,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,371,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,84,PSIVISSIG0002_84,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,85,PSIVISSIG0002_85,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,PSIVISSIG0002_86,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,87,PSIVISSIG0002_87,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,486,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,88,PSIVISSIG0002_88,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,PSIVISSIG0002_89,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,493,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,90,PSIVISSIG0002_90,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,91,PSIVISSIG0002_91,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,92,PSIVISSIG0002_92,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,93,PSIVISSIG0002_93,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,812,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,94,PSIVISSIG0002_94,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,95,PSIVISSIG0002_95,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,328,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,96,PSIVISSIG0002_96,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,97,PSIVISSIG0002_97,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,PSIVISSIG0002_98,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,82,1,Censored at the last contact date,DEATH
PSIVISSIG0002,99,PSIVISSIG0002_99,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1087,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,100,PSIVISSIG0002_100,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,699,1,Censored at the last contact date,DEATH
PSIVISSIG0002,101,PSIVISSIG0002_101,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,193,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,102,PSIVISSIG0002_102,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,103,PSIVISSIG0002_103,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,104,PSIVISSIG0002_104,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,105,PSIVISSIG0002_105,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,39,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,106,PSIVISSIG0002_106,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,334,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,107,PSIVISSIG0002_107,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,108,PSIVISSIG0002_108,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,109,PSIVISSIG0002_109,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,110,PSIVISSIG0002_110,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,84,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,111,PSIVISSIG0002_111,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,112,PSIVISSIG0002_112,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,45,1,Censored at the last contact date,DEATH
PSIVISSIG0002,113,PSIVISSIG0002_113,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,PSIVISSIG0002_114,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,115,PSIVISSIG0002_115,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,85,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,116,PSIVISSIG0002_116,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,PSIVISSIG0002_117,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,PSIVISSIG0002_118,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,PSIVISSIG0002_119,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,120,PSIVISSIG0002_120,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,121,PSIVISSIG0002_121,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,PSIVISSIG0002_122,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,123,PSIVISSIG0002_123,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,124,PSIVISSIG0002_124,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1016,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,125,PSIVISSIG0002_125,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,126,PSIVISSIG0002_126,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,127,PSIVISSIG0002_127,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,128,PSIVISSIG0002_128,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,129,PSIVISSIG0002_129,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,PSIVISSIG0002_130,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,131,PSIVISSIG0002_131,66,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,132,PSIVISSIG0002_132,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,133,PSIVISSIG0002_133,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1729,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,134,PSIVISSIG0002_134,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,135,PSIVISSIG0002_135,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,PSIVISSIG0002_136,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,137,PSIVISSIG0002_137,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,PSIVISSIG0002_138,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,72,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,139,PSIVISSIG0002_139,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1054,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,140,PSIVISSIG0002_140,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,141,PSIVISSIG0002_141,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,PSIVISSIG0002_142,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,300,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,143,PSIVISSIG0002_143,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,574,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,144,PSIVISSIG0002_144,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,145,PSIVISSIG0002_145,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,146,PSIVISSIG0002_146,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,147,PSIVISSIG0002_147,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,148,PSIVISSIG0002_148,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,246,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,149,PSIVISSIG0002_149,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,150,PSIVISSIG0002_150,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,PSIVISSIG0002_151,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,152,PSIVISSIG0002_152,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,153,PSIVISSIG0002_153,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,PSIVISSIG0002_154,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,592,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,PSIVISSIG0002_155,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,156,PSIVISSIG0002_156,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,157,PSIVISSIG0002_157,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,158,PSIVISSIG0002_158,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,159,PSIVISSIG0002_159,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,612,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,160,PSIVISSIG0002_160,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,PSIVISSIG0002_161,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,PSIVISSIG0002_162,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,163,PSIVISSIG0002_163,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,PSIVISSIG0002_164,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,165,PSIVISSIG0002_165,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,914,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,166,PSIVISSIG0002_166,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,999,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,167,PSIVISSIG0002_167,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1013,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,168,PSIVISSIG0002_168,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,169,PSIVISSIG0002_169,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,170,PSIVISSIG0002_170,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,171,PSIVISSIG0002_171,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,917,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,172,PSIVISSIG0002_172,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,173,PSIVISSIG0002_173,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,174,PSIVISSIG0002_174,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,DEATH
PSIVISSIG0002,175,PSIVISSIG0002_175,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,PSIVISSIG0002_176,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,177,PSIVISSIG0002_177,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,178,PSIVISSIG0002_178,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,179,PSIVISSIG0002_179,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,180,PSIVISSIG0002_180,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,261,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,181,PSIVISSIG0002_181,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,79,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,PSIVISSIG0002_182,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,183,PSIVISSIG0002_183,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,184,PSIVISSIG0002_184,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,185,PSIVISSIG0002_185,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1708,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,186,PSIVISSIG0002_186,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,187,PSIVISSIG0002_187,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,188,PSIVISSIG0002_188,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,189,PSIVISSIG0002_189,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,190,PSIVISSIG0002_190,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,191,PSIVISSIG0002_191,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1410,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,192,PSIVISSIG0002_192,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,512,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,193,PSIVISSIG0002_193,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,194,PSIVISSIG0002_194,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,195,PSIVISSIG0002_195,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,493,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,196,PSIVISSIG0002_196,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,197,PSIVISSIG0002_197,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,198,PSIVISSIG0002_198,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,199,PSIVISSIG0002_199,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,PSIVISSIG0002_200,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,201,PSIVISSIG0002_201,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,PSIVISSIG0002_202,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,203,PSIVISSIG0002_203,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,43,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,204,PSIVISSIG0002_204,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1581,1,Censored at the last contact date,DEATH
PSIVISSIG0002,205,PSIVISSIG0002_205,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,206,PSIVISSIG0002_206,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,PSIVISSIG0002_207,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,208,PSIVISSIG0002_208,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,209,PSIVISSIG0002_209,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,107,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,210,PSIVISSIG0002_210,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,360,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,211,PSIVISSIG0002_211,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,212,PSIVISSIG0002_212,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,835,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,213,PSIVISSIG0002_213,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,214,PSIVISSIG0002_214,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,215,PSIVISSIG0002_215,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,216,PSIVISSIG0002_216,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,217,PSIVISSIG0002_217,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,218,PSIVISSIG0002_218,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,219,PSIVISSIG0002_219,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,220,PSIVISSIG0002_220,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,PSIVISSIG0002_221,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1739,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,222,PSIVISSIG0002_222,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,554,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,223,PSIVISSIG0002_223,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,224,PSIVISSIG0002_224,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,225,PSIVISSIG0002_225,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,648,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,226,PSIVISSIG0002_226,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,227,PSIVISSIG0002_227,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,228,PSIVISSIG0002_228,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,229,PSIVISSIG0002_229,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,PSIVISSIG0002_230,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1351,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,231,PSIVISSIG0002_231,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,232,PSIVISSIG0002_232,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,233,PSIVISSIG0002_233,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,234,PSIVISSIG0002_234,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,DEATH
PSIVISSIG0002,235,PSIVISSIG0002_235,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,236,PSIVISSIG0002_236,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,237,PSIVISSIG0002_237,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1182,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,238,PSIVISSIG0002_238,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,239,PSIVISSIG0002_239,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,321,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,240,PSIVISSIG0002_240,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,241,PSIVISSIG0002_241,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,559,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,242,PSIVISSIG0002_242,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,243,PSIVISSIG0002_243,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,244,PSIVISSIG0002_244,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,245,PSIVISSIG0002_245,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,180,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,246,PSIVISSIG0002_246,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,247,PSIVISSIG0002_247,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1110,1,Censored at the last contact date,DEATH
PSIVISSIG0002,248,PSIVISSIG0002_248,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,269,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,249,PSIVISSIG0002_249,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,PSIVISSIG0002_250,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1309,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,251,PSIVISSIG0002_251,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,PSIVISSIG0002_252,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,253,PSIVISSIG0002_253,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,254,PSIVISSIG0002_254,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,255,PSIVISSIG0002_255,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,256,PSIVISSIG0002_256,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,257,PSIVISSIG0002_257,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,258,PSIVISSIG0002_258,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,259,PSIVISSIG0002_259,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,260,PSIVISSIG0002_260,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,261,PSIVISSIG0002_261,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,PSIVISSIG0002_262,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1768,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,263,PSIVISSIG0002_263,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,264,PSIVISSIG0002_264,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,PSIVISSIG0002_265,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1077,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,266,PSIVISSIG0002_266,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1079,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,267,PSIVISSIG0002_267,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,268,PSIVISSIG0002_268,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,269,PSIVISSIG0002_269,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,562,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,PSIVISSIG0002_270,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,271,PSIVISSIG0002_271,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,272,PSIVISSIG0002_272,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,273,PSIVISSIG0002_273,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,139,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,PSIVISSIG0002_274,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,275,PSIVISSIG0002_275,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,276,PSIVISSIG0002_276,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,484,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,277,PSIVISSIG0002_277,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,278,PSIVISSIG0002_278,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,279,PSIVISSIG0002_279,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,993,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,280,PSIVISSIG0002_280,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,DEATH
PSIVISSIG0002,281,PSIVISSIG0002_281,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,282,PSIVISSIG0002_282,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,283,PSIVISSIG0002_283,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,284,PSIVISSIG0002_284,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,8,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,285,PSIVISSIG0002_285,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,286,PSIVISSIG0002_286,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,287,PSIVISSIG0002_287,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,288,PSIVISSIG0002_288,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,701,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,289,PSIVISSIG0002_289,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,290,PSIVISSIG0002_290,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,291,PSIVISSIG0002_291,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1084,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,292,PSIVISSIG0002_292,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,327,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,293,PSIVISSIG0002_293,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,196,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,294,PSIVISSIG0002_294,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,295,PSIVISSIG0002_295,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,543,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,296,PSIVISSIG0002_296,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,297,PSIVISSIG0002_297,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,298,PSIVISSIG0002_298,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,299,PSIVISSIG0002_299,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,48,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,300,PSIVISSIG0002_300,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,825,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,301,PSIVISSIG0002_301,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,302,PSIVISSIG0002_302,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,200,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,303,PSIVISSIG0002_303,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,241,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,304,PSIVISSIG0002_304,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,966,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,305,PSIVISSIG0002_305,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,306,PSIVISSIG0002_306,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,PSIVISSIG0002_307,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1511,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,PSIVISSIG0002_308,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,309,PSIVISSIG0002_309,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,310,PSIVISSIG0002_310,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,311,PSIVISSIG0002_311,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,312,PSIVISSIG0002_312,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,107,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,313,PSIVISSIG0002_313,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,314,PSIVISSIG0002_314,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,315,PSIVISSIG0002_315,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,316,PSIVISSIG0002_316,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,PSIVISSIG0002_317,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,318,PSIVISSIG0002_318,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,319,PSIVISSIG0002_319,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,320,PSIVISSIG0002_320,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,321,PSIVISSIG0002_321,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,322,PSIVISSIG0002_322,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,323,PSIVISSIG0002_323,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,313,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,324,PSIVISSIG0002_324,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,325,PSIVISSIG0002_325,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,326,PSIVISSIG0002_326,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,PSIVISSIG0002_327,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,181,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,328,PSIVISSIG0002_328,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,329,PSIVISSIG0002_329,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1035,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,330,PSIVISSIG0002_330,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,331,PSIVISSIG0002_331,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,806,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,332,PSIVISSIG0002_332,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,333,PSIVISSIG0002_333,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,101,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,334,PSIVISSIG0002_334,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,335,PSIVISSIG0002_335,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,426,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,PSIVISSIG0002_336,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,337,PSIVISSIG0002_337,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,195,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,338,PSIVISSIG0002_338,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,339,PSIVISSIG0002_339,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,346,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,PSIVISSIG0002_340,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1762,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,341,PSIVISSIG0002_341,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,342,PSIVISSIG0002_342,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,343,PSIVISSIG0002_343,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,344,PSIVISSIG0002_344,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,898,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,345,PSIVISSIG0002_345,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,346,PSIVISSIG0002_346,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,PSIVISSIG0002_347,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,348,PSIVISSIG0002_348,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,349,PSIVISSIG0002_349,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,954,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,350,PSIVISSIG0002_350,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,579,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,351,PSIVISSIG0002_351,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,352,PSIVISSIG0002_352,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,890,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,353,PSIVISSIG0002_353,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,354,PSIVISSIG0002_354,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,355,PSIVISSIG0002_355,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,747,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,356,PSIVISSIG0002_356,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,994,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,357,PSIVISSIG0002_357,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,358,PSIVISSIG0002_358,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,359,PSIVISSIG0002_359,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,360,PSIVISSIG0002_360,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,361,PSIVISSIG0002_361,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,362,PSIVISSIG0002_362,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,363,PSIVISSIG0002_363,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,364,PSIVISSIG0002_364,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,670,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,365,PSIVISSIG0002_365,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,366,PSIVISSIG0002_366,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,367,PSIVISSIG0002_367,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1001,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,368,PSIVISSIG0002_368,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,369,PSIVISSIG0002_369,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,370,PSIVISSIG0002_370,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,371,PSIVISSIG0002_371,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,372,PSIVISSIG0002_372,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,373,PSIVISSIG0002_373,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,374,PSIVISSIG0002_374,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,945,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,PSIVISSIG0002_375,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,376,PSIVISSIG0002_376,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,377,PSIVISSIG0002_377,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,675,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,PSIVISSIG0002_378,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,379,PSIVISSIG0002_379,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,161,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,380,PSIVISSIG0002_380,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,381,PSIVISSIG0002_381,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,382,PSIVISSIG0002_382,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1415,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,383,PSIVISSIG0002_383,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,177,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,384,PSIVISSIG0002_384,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,119,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,PSIVISSIG0002_385,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,386,PSIVISSIG0002_386,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,387,PSIVISSIG0002_387,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,388,PSIVISSIG0002_388,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,389,PSIVISSIG0002_389,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,390,PSIVISSIG0002_390,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,74,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,391,PSIVISSIG0002_391,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,392,PSIVISSIG0002_392,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,382,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,393,PSIVISSIG0002_393,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,394,PSIVISSIG0002_394,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,DEATH
PSIVISSIG0002,395,PSIVISSIG0002_395,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,396,PSIVISSIG0002_396,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,539,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,PSIVISSIG0002_397,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,398,PSIVISSIG0002_398,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,158,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,399,PSIVISSIG0002_399,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,400,PSIVISSIG0002_400,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,401,PSIVISSIG0002_401,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,83,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,402,PSIVISSIG0002_402,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,403,PSIVISSIG0002_403,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,404,PSIVISSIG0002_404,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1257,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,405,PSIVISSIG0002_405,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,406,PSIVISSIG0002_406,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,407,PSIVISSIG0002_407,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,408,PSIVISSIG0002_408,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,PSIVISSIG0002_409,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,410,PSIVISSIG0002_410,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,254,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,411,PSIVISSIG0002_411,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,490,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,412,PSIVISSIG0002_412,69,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,184,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,413,PSIVISSIG0002_413,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,414,PSIVISSIG0002_414,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,760,1,Censored at the last contact date,DEATH
PSIVISSIG0002,415,PSIVISSIG0002_415,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,416,PSIVISSIG0002_416,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,DEATH
PSIVISSIG0002,417,PSIVISSIG0002_417,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,418,PSIVISSIG0002_418,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,419,PSIVISSIG0002_419,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,420,PSIVISSIG0002_420,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,421,PSIVISSIG0002_421,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,422,PSIVISSIG0002_422,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,423,PSIVISSIG0002_423,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,142,1,Censored at the last contact date,DEATH
PSIVISSIG0002,424,PSIVISSIG0002_424,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,425,PSIVISSIG0002_425,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,426,PSIVISSIG0002_426,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,427,PSIVISSIG0002_427,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,163,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,428,PSIVISSIG0002_428,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1294,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,429,PSIVISSIG0002_429,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,PSIVISSIG0002_430,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,PSIVISSIG0002_431,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,432,PSIVISSIG0002_432,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,433,PSIVISSIG0002_433,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,434,PSIVISSIG0002_434,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,435,PSIVISSIG0002_435,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,152,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,436,PSIVISSIG0002_436,77,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,437,PSIVISSIG0002_437,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,438,PSIVISSIG0002_438,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,439,PSIVISSIG0002_439,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,281,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,440,PSIVISSIG0002_440,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,441,PSIVISSIG0002_441,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,64,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,442,PSIVISSIG0002_442,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,443,PSIVISSIG0002_443,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,444,PSIVISSIG0002_444,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,445,PSIVISSIG0002_445,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,PSIVISSIG0002_446,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,447,PSIVISSIG0002_447,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,448,PSIVISSIG0002_448,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,449,PSIVISSIG0002_449,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,749,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,450,PSIVISSIG0002_450,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,331,1,Censored at the last contact date,DEATH
PSIVISSIG0002,451,PSIVISSIG0002_451,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,421,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,452,PSIVISSIG0002_452,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,453,PSIVISSIG0002_453,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,960,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,PSIVISSIG0002_454,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,455,PSIVISSIG0002_455,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,456,PSIVISSIG0002_456,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,457,PSIVISSIG0002_457,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,831,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,458,PSIVISSIG0002_458,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,459,PSIVISSIG0002_459,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,460,PSIVISSIG0002_460,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,461,PSIVISSIG0002_461,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,859,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,462,PSIVISSIG0002_462,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,463,PSIVISSIG0002_463,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,464,PSIVISSIG0002_464,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1043,1,Censored at the last contact date,DEATH
PSIVISSIG0002,465,PSIVISSIG0002_465,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1371,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,466,PSIVISSIG0002_466,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,372,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,467,PSIVISSIG0002_467,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,52,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,468,PSIVISSIG0002_468,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,469,PSIVISSIG0002_469,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,470,PSIVISSIG0002_470,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,471,PSIVISSIG0002_471,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,PSIVISSIG0002_472,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,47,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,473,PSIVISSIG0002_473,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,127,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,474,PSIVISSIG0002_474,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,PSIVISSIG0002_475,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,919,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,476,PSIVISSIG0002_476,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,633,1,Censored at the last contact date,DEATH
PSIVISSIG0002,477,PSIVISSIG0002_477,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,478,PSIVISSIG0002_478,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,479,PSIVISSIG0002_479,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,480,PSIVISSIG0002_480,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,847,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,481,PSIVISSIG0002_481,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,PSIVISSIG0002_482,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,483,PSIVISSIG0002_483,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,484,PSIVISSIG0002_484,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,485,PSIVISSIG0002_485,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,486,PSIVISSIG0002_486,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,487,PSIVISSIG0002_487,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,488,PSIVISSIG0002_488,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,786,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,489,PSIVISSIG0002_489,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,PSIVISSIG0002_490,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,491,PSIVISSIG0002_491,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,397,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,492,PSIVISSIG0002_492,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,493,PSIVISSIG0002_493,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,427,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,494,PSIVISSIG0002_494,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,495,PSIVISSIG0002_495,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,496,PSIVISSIG0002_496,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,497,PSIVISSIG0002_497,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,498,PSIVISSIG0002_498,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,499,PSIVISSIG0002_499,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1626,1,Censored at the last contact date,DEATH
PSIVISSIG0002,500,PSIVISSIG0002_500,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,964,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,501,PSIVISSIG0002_501,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,502,PSIVISSIG0002_502,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,91,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,PSIVISSIG0002_503,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,504,PSIVISSIG0002_504,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,505,PSIVISSIG0002_505,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,506,PSIVISSIG0002_506,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,507,PSIVISSIG0002_507,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,508,PSIVISSIG0002_508,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,567,1,Censored at the last contact date,DEATH
PSIVISSIG0002,509,PSIVISSIG0002_509,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,DEATH
PSIVISSIG0002,510,PSIVISSIG0002_510,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,511,PSIVISSIG0002_511,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,512,PSIVISSIG0002_512,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1654,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,513,PSIVISSIG0002_513,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,713,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,514,PSIVISSIG0002_514,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,515,PSIVISSIG0002_515,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,PSIVISSIG0002_516,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,517,PSIVISSIG0002_517,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1552,1,Censored at the last contact date,DEATH
PSIVISSIG0002,518,PSIVISSIG0002_518,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,PSIVISSIG0002_519,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1517,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,520,PSIVISSIG0002_520,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,521,PSIVISSIG0002_521,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1624,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,522,PSIVISSIG0002_522,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,523,PSIVISSIG0002_523,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,524,PSIVISSIG0002_524,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,525,PSIVISSIG0002_525,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,526,PSIVISSIG0002_526,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,527,PSIVISSIG0002_527,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,528,PSIVISSIG0002_528,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,529,PSIVISSIG0002_529,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,530,PSIVISSIG0002_530,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,143,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,531,PSIVISSIG0002_531,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,PSIVISSIG0002_532,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,533,PSIVISSIG0002_533,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,534,PSIVISSIG0002_534,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,535,PSIVISSIG0002_535,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,83,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,536,PSIVISSIG0002_536,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1528,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,537,PSIVISSIG0002_537,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,538,PSIVISSIG0002_538,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,539,PSIVISSIG0002_539,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,PSIVISSIG0002_540,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,541,PSIVISSIG0002_541,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,542,PSIVISSIG0002_542,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,543,PSIVISSIG0002_543,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,544,PSIVISSIG0002_544,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,DEATH
PSIVISSIG0002,545,PSIVISSIG0002_545,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,886,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,546,PSIVISSIG0002_546,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,547,PSIVISSIG0002_547,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,548,PSIVISSIG0002_548,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,485,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,549,PSIVISSIG0002_549,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,550,PSIVISSIG0002_550,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,551,PSIVISSIG0002_551,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,552,PSIVISSIG0002_552,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,553,PSIVISSIG0002_553,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,644,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,PSIVISSIG0002_554,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,555,PSIVISSIG0002_555,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,491,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,556,PSIVISSIG0002_556,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,557,PSIVISSIG0002_557,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,558,PSIVISSIG0002_558,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,559,PSIVISSIG0002_559,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,560,PSIVISSIG0002_560,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,561,PSIVISSIG0002_561,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,PSIVISSIG0002_562,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,563,PSIVISSIG0002_563,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,564,PSIVISSIG0002_564,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,565,PSIVISSIG0002_565,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1052,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,566,PSIVISSIG0002_566,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,567,PSIVISSIG0002_567,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,PSIVISSIG0002_568,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,688,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,569,PSIVISSIG0002_569,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,570,PSIVISSIG0002_570,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,PSIVISSIG0002_571,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,DEATH
PSIVISSIG0002,572,PSIVISSIG0002_572,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,573,PSIVISSIG0002_573,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,574,PSIVISSIG0002_574,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,575,PSIVISSIG0002_575,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,332,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,576,PSIVISSIG0002_576,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,PSIVISSIG0002_577,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,578,PSIVISSIG0002_578,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,PSIVISSIG0002_579,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,580,PSIVISSIG0002_580,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,581,PSIVISSIG0002_581,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,582,PSIVISSIG0002_582,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,77,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,583,PSIVISSIG0002_583,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,280,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,584,PSIVISSIG0002_584,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,PSIVISSIG0002_585,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,586,PSIVISSIG0002_586,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,587,PSIVISSIG0002_587,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,588,PSIVISSIG0002_588,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,589,PSIVISSIG0002_589,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,590,PSIVISSIG0002_590,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,PSIVISSIG0002_591,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,592,PSIVISSIG0002_592,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,340,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,593,PSIVISSIG0002_593,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,594,PSIVISSIG0002_594,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,PSIVISSIG0002_595,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,772,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,596,PSIVISSIG0002_596,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,597,PSIVISSIG0002_597,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1632,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,598,PSIVISSIG0002_598,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,599,PSIVISSIG0002_599,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,600,PSIVISSIG0002_600,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,20,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,601,PSIVISSIG0002_601,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,602,PSIVISSIG0002_602,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,313,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,603,PSIVISSIG0002_603,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,604,PSIVISSIG0002_604,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,605,PSIVISSIG0002_605,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,606,PSIVISSIG0002_606,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,607,PSIVISSIG0002_607,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,PSIVISSIG0002_608,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,609,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,609,PSIVISSIG0002_609,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,610,PSIVISSIG0002_610,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,623,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,611,PSIVISSIG0002_611,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,612,PSIVISSIG0002_612,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,613,PSIVISSIG0002_613,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,614,PSIVISSIG0002_614,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,615,PSIVISSIG0002_615,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,616,PSIVISSIG0002_616,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,PSIVISSIG0002_617,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,618,PSIVISSIG0002_618,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,619,PSIVISSIG0002_619,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,620,PSIVISSIG0002_620,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,621,PSIVISSIG0002_621,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,622,PSIVISSIG0002_622,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,629,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,PSIVISSIG0002_623,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,624,PSIVISSIG0002_624,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,625,PSIVISSIG0002_625,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,626,PSIVISSIG0002_626,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,627,PSIVISSIG0002_627,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,628,PSIVISSIG0002_628,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,629,PSIVISSIG0002_629,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,630,PSIVISSIG0002_630,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,631,PSIVISSIG0002_631,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,785,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,632,PSIVISSIG0002_632,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,852,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,633,PSIVISSIG0002_633,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,634,PSIVISSIG0002_634,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,635,PSIVISSIG0002_635,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,440,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,636,PSIVISSIG0002_636,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1674,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,637,PSIVISSIG0002_637,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,573,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,638,PSIVISSIG0002_638,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,639,PSIVISSIG0002_639,67,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,640,PSIVISSIG0002_640,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,PSIVISSIG0002_641,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,642,PSIVISSIG0002_642,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,55,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,643,PSIVISSIG0002_643,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,644,PSIVISSIG0002_644,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,645,PSIVISSIG0002_645,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,646,PSIVISSIG0002_646,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,647,PSIVISSIG0002_647,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1707,1,Censored at the last contact date,DEATH
PSIVISSIG0002,648,PSIVISSIG0002_648,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,649,PSIVISSIG0002_649,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,439,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,650,PSIVISSIG0002_650,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,651,PSIVISSIG0002_651,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,818,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,PSIVISSIG0002_652,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,653,PSIVISSIG0002_653,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1171,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,654,PSIVISSIG0002_654,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,655,PSIVISSIG0002_655,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,704,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,656,PSIVISSIG0002_656,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,PSIVISSIG0002_657,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,832,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,658,PSIVISSIG0002_658,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,189,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,PSIVISSIG0002_659,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,660,PSIVISSIG0002_660,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,661,PSIVISSIG0002_661,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,288,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,662,PSIVISSIG0002_662,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,663,PSIVISSIG0002_663,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,150,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,664,PSIVISSIG0002_664,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,220,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,665,PSIVISSIG0002_665,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,666,PSIVISSIG0002_666,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,716,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,667,PSIVISSIG0002_667,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,668,PSIVISSIG0002_668,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,718,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,669,PSIVISSIG0002_669,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,466,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,670,PSIVISSIG0002_670,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1498,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,671,PSIVISSIG0002_671,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,672,PSIVISSIG0002_672,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,673,PSIVISSIG0002_673,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1387,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,674,PSIVISSIG0002_674,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,675,PSIVISSIG0002_675,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,DEATH
PSIVISSIG0002,676,PSIVISSIG0002_676,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,94,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,677,PSIVISSIG0002_677,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,901,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,678,PSIVISSIG0002_678,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,679,PSIVISSIG0002_679,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,998,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,680,PSIVISSIG0002_680,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,681,PSIVISSIG0002_681,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,682,PSIVISSIG0002_682,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,683,PSIVISSIG0002_683,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,684,PSIVISSIG0002_684,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,685,PSIVISSIG0002_685,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,686,PSIVISSIG0002_686,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,673,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,PSIVISSIG0002_687,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,688,PSIVISSIG0002_688,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,689,PSIVISSIG0002_689,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,37,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,690,PSIVISSIG0002_690,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,691,PSIVISSIG0002_691,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,PSIVISSIG0002_692,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1494,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,PSIVISSIG0002_693,47,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,16,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,694,PSIVISSIG0002_694,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,695,PSIVISSIG0002_695,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,810,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,696,PSIVISSIG0002_696,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,501,1,Censored at the last contact date,DEATH
PSIVISSIG0002,697,PSIVISSIG0002_697,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,698,PSIVISSIG0002_698,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,699,PSIVISSIG0002_699,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,700,PSIVISSIG0002_700,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,701,PSIVISSIG0002_701,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,702,PSIVISSIG0002_702,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,874,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,703,PSIVISSIG0002_703,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1096,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,704,PSIVISSIG0002_704,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,705,PSIVISSIG0002_705,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,903,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,PSIVISSIG0002_706,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1709,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,707,PSIVISSIG0002_707,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,708,PSIVISSIG0002_708,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,709,PSIVISSIG0002_709,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,710,PSIVISSIG0002_710,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,PSIVISSIG0002_711,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,712,PSIVISSIG0002_712,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,713,PSIVISSIG0002_713,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,714,PSIVISSIG0002_714,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,415,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,715,PSIVISSIG0002_715,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,716,PSIVISSIG0002_716,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,717,PSIVISSIG0002_717,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,856,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,718,PSIVISSIG0002_718,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,719,PSIVISSIG0002_719,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,477,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,PSIVISSIG0002_720,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,721,PSIVISSIG0002_721,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,722,PSIVISSIG0002_722,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,723,PSIVISSIG0002_723,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,430,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,PSIVISSIG0002_724,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,267,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,725,PSIVISSIG0002_725,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,PSIVISSIG0002_726,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,727,PSIVISSIG0002_727,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,PSIVISSIG0002_728,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,729,PSIVISSIG0002_729,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,730,PSIVISSIG0002_730,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,731,PSIVISSIG0002_731,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,PSIVISSIG0002_732,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,24,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,733,PSIVISSIG0002_733,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,734,PSIVISSIG0002_734,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,735,PSIVISSIG0002_735,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,736,PSIVISSIG0002_736,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,737,PSIVISSIG0002_737,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1197,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,738,PSIVISSIG0002_738,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,739,PSIVISSIG0002_739,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,740,PSIVISSIG0002_740,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,741,PSIVISSIG0002_741,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,742,PSIVISSIG0002_742,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,743,PSIVISSIG0002_743,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,212,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,744,PSIVISSIG0002_744,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,745,PSIVISSIG0002_745,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,PSIVISSIG0002_746,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,747,PSIVISSIG0002_747,26,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,748,PSIVISSIG0002_748,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,347,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,749,PSIVISSIG0002_749,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,35,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,750,PSIVISSIG0002_750,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,751,PSIVISSIG0002_751,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,752,PSIVISSIG0002_752,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,173,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,753,PSIVISSIG0002_753,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1408,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,PSIVISSIG0002_754,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,PSIVISSIG0002_755,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,756,PSIVISSIG0002_756,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,757,PSIVISSIG0002_757,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,758,PSIVISSIG0002_758,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,759,PSIVISSIG0002_759,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,760,PSIVISSIG0002_760,65,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,PSIVISSIG0002_761,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,PSIVISSIG0002_762,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1143,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,763,PSIVISSIG0002_763,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,DEATH
PSIVISSIG0002,764,PSIVISSIG0002_764,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,765,PSIVISSIG0002_765,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1269,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,766,PSIVISSIG0002_766,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,767,PSIVISSIG0002_767,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,768,PSIVISSIG0002_768,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1616,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,769,PSIVISSIG0002_769,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,555,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,770,PSIVISSIG0002_770,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,771,PSIVISSIG0002_771,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,772,PSIVISSIG0002_772,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,773,PSIVISSIG0002_773,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,774,PSIVISSIG0002_774,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,775,PSIVISSIG0002_775,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,776,PSIVISSIG0002_776,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,900,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,777,PSIVISSIG0002_777,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,778,PSIVISSIG0002_778,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,779,PSIVISSIG0002_779,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,780,PSIVISSIG0002_780,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,781,PSIVISSIG0002_781,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,782,PSIVISSIG0002_782,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,783,PSIVISSIG0002_783,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,784,PSIVISSIG0002_784,62,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,785,PSIVISSIG0002_785,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,786,PSIVISSIG0002_786,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,787,PSIVISSIG0002_787,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,567,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,788,PSIVISSIG0002_788,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,789,PSIVISSIG0002_789,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,790,PSIVISSIG0002_790,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,791,PSIVISSIG0002_791,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,792,PSIVISSIG0002_792,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,793,PSIVISSIG0002_793,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,794,PSIVISSIG0002_794,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1414,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,795,PSIVISSIG0002_795,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,663,1,Censored at the last contact date,DEATH
PSIVISSIG0002,796,PSIVISSIG0002_796,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,797,PSIVISSIG0002_797,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,620,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,798,PSIVISSIG0002_798,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,799,PSIVISSIG0002_799,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,800,PSIVISSIG0002_800,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,801,PSIVISSIG0002_801,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,802,PSIVISSIG0002_802,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,805,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,803,PSIVISSIG0002_803,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,99,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,804,PSIVISSIG0002_804,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,805,PSIVISSIG0002_805,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,476,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,806,PSIVISSIG0002_806,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,807,PSIVISSIG0002_807,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,808,PSIVISSIG0002_808,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,809,PSIVISSIG0002_809,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,218,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,810,PSIVISSIG0002_810,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,811,PSIVISSIG0002_811,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,PSIVISSIG0002_812,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,813,PSIVISSIG0002_813,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,PSIVISSIG0002_814,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,815,PSIVISSIG0002_815,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,DEATH
PSIVISSIG0002,816,PSIVISSIG0002_816,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,817,PSIVISSIG0002_817,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,818,PSIVISSIG0002_818,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,819,PSIVISSIG0002_819,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,820,PSIVISSIG0002_820,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,510,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,821,PSIVISSIG0002_821,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,822,PSIVISSIG0002_822,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,823,PSIVISSIG0002_823,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,531,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,PSIVISSIG0002_824,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,825,PSIVISSIG0002_825,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,PSIVISSIG0002_826,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,442,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,827,PSIVISSIG0002_827,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1231,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,828,PSIVISSIG0002_828,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,829,PSIVISSIG0002_829,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,830,PSIVISSIG0002_830,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1158,1,Censored at the last contact date,DEATH
PSIVISSIG0002,831,PSIVISSIG0002_831,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,832,PSIVISSIG0002_832,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,251,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,833,PSIVISSIG0002_833,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,834,PSIVISSIG0002_834,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,835,PSIVISSIG0002_835,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,450,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,836,PSIVISSIG0002_836,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,PSIVISSIG0002_837,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,638,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,PSIVISSIG0002_838,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,839,PSIVISSIG0002_839,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,840,PSIVISSIG0002_840,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,841,PSIVISSIG0002_841,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,509,1,Censored at the last contact date,DEATH
PSIVISSIG0002,842,PSIVISSIG0002_842,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,450,1,Censored at the last contact date,DEATH
PSIVISSIG0002,843,PSIVISSIG0002_843,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,844,PSIVISSIG0002_844,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,865,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,845,PSIVISSIG0002_845,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,846,PSIVISSIG0002_846,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,703,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,847,PSIVISSIG0002_847,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,848,PSIVISSIG0002_848,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,849,PSIVISSIG0002_849,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,850,PSIVISSIG0002_850,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,851,PSIVISSIG0002_851,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,852,PSIVISSIG0002_852,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,PSIVISSIG0002_853,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,PSIVISSIG0002_854,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,896,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,855,PSIVISSIG0002_855,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1070,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,856,PSIVISSIG0002_856,64,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,857,PSIVISSIG0002_857,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,370,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,858,PSIVISSIG0002_858,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1642,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,859,PSIVISSIG0002_859,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,PSIVISSIG0002_860,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,644,1,Censored at the last contact date,DEATH
PSIVISSIG0002,861,PSIVISSIG0002_861,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,862,PSIVISSIG0002_862,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,361,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,863,PSIVISSIG0002_863,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1061,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,864,PSIVISSIG0002_864,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,PSIVISSIG0002_865,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,478,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,PSIVISSIG0002_866,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,PSIVISSIG0002_867,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,952,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,868,PSIVISSIG0002_868,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,585,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,869,PSIVISSIG0002_869,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,348,1,Censored at the last contact date,DEATH
PSIVISSIG0002,870,PSIVISSIG0002_870,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,871,PSIVISSIG0002_871,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,872,PSIVISSIG0002_872,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,619,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,873,PSIVISSIG0002_873,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,874,PSIVISSIG0002_874,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,875,PSIVISSIG0002_875,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,624,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,876,PSIVISSIG0002_876,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,877,PSIVISSIG0002_877,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,62,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,878,PSIVISSIG0002_878,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,PSIVISSIG0002_879,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,880,PSIVISSIG0002_880,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,881,PSIVISSIG0002_881,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,82,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,PSIVISSIG0002_882,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1389,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,883,PSIVISSIG0002_883,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,884,PSIVISSIG0002_884,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1419,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,885,PSIVISSIG0002_885,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,38,1,Censored at the last contact date,DEATH
PSIVISSIG0002,886,PSIVISSIG0002_886,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,51,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,887,PSIVISSIG0002_887,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,888,PSIVISSIG0002_888,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,1,Censored at the last contact date,DEATH
PSIVISSIG0002,889,PSIVISSIG0002_889,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1562,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,890,PSIVISSIG0002_890,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,PSIVISSIG0002_891,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1611,1,Censored at the last contact date,DEATH
PSIVISSIG0002,892,PSIVISSIG0002_892,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,DEATH
PSIVISSIG0002,893,PSIVISSIG0002_893,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,894,PSIVISSIG0002_894,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,895,PSIVISSIG0002_895,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,788,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,896,PSIVISSIG0002_896,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,897,PSIVISSIG0002_897,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,969,1,Censored at the last contact date,DEATH
PSIVISSIG0002,898,PSIVISSIG0002_898,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,899,PSIVISSIG0002_899,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,50,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,900,PSIVISSIG0002_900,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,901,PSIVISSIG0002_901,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,902,PSIVISSIG0002_902,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,903,PSIVISSIG0002_903,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,568,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,904,PSIVISSIG0002_904,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,PSIVISSIG0002_905,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1137,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,906,PSIVISSIG0002_906,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,907,PSIVISSIG0002_907,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,PSIVISSIG0002_908,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,909,PSIVISSIG0002_909,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,710,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,910,PSIVISSIG0002_910,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,911,PSIVISSIG0002_911,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,912,PSIVISSIG0002_912,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1574,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,PSIVISSIG0002_913,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,914,PSIVISSIG0002_914,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,PSIVISSIG0002_915,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1421,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,916,PSIVISSIG0002_916,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,917,PSIVISSIG0002_917,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,918,PSIVISSIG0002_918,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,919,PSIVISSIG0002_919,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,920,PSIVISSIG0002_920,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,921,PSIVISSIG0002_921,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,922,PSIVISSIG0002_922,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,923,PSIVISSIG0002_923,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,924,PSIVISSIG0002_924,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1152,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,925,PSIVISSIG0002_925,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,926,PSIVISSIG0002_926,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,927,PSIVISSIG0002_927,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,690,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,928,PSIVISSIG0002_928,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1166,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,929,PSIVISSIG0002_929,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,433,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,930,PSIVISSIG0002_930,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,647,1,Censored at the last contact date,DEATH
PSIVISSIG0002,931,PSIVISSIG0002_931,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1027,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,932,PSIVISSIG0002_932,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,348,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,933,PSIVISSIG0002_933,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,934,PSIVISSIG0002_934,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,935,PSIVISSIG0002_935,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,872,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,936,PSIVISSIG0002_936,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,937,PSIVISSIG0002_937,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1486,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,938,PSIVISSIG0002_938,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,965,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,939,PSIVISSIG0002_939,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,940,PSIVISSIG0002_940,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1244,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,941,PSIVISSIG0002_941,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,942,PSIVISSIG0002_942,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,PSIVISSIG0002_943,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,944,PSIVISSIG0002_944,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,945,PSIVISSIG0002_945,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,946,PSIVISSIG0002_946,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,947,PSIVISSIG0002_947,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,948,PSIVISSIG0002_948,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,949,PSIVISSIG0002_949,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,950,PSIVISSIG0002_950,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,951,PSIVISSIG0002_951,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,325,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,952,PSIVISSIG0002_952,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,953,PSIVISSIG0002_953,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,PSIVISSIG0002_954,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,955,PSIVISSIG0002_955,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,956,PSIVISSIG0002_956,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1036,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,PSIVISSIG0002_957,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1406,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,958,PSIVISSIG0002_958,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,395,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,959,PSIVISSIG0002_959,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,960,PSIVISSIG0002_960,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,961,PSIVISSIG0002_961,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,553,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,962,PSIVISSIG0002_962,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,963,PSIVISSIG0002_963,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,PSIVISSIG0002_964,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,965,PSIVISSIG0002_965,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,PSIVISSIG0002_966,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,967,PSIVISSIG0002_967,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,PSIVISSIG0002_968,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1064,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,PSIVISSIG0002_969,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,377,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,970,PSIVISSIG0002_970,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,76,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,971,PSIVISSIG0002_971,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,972,PSIVISSIG0002_972,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1138,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,973,PSIVISSIG0002_973,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,974,PSIVISSIG0002_974,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,975,PSIVISSIG0002_975,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,976,PSIVISSIG0002_976,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,977,PSIVISSIG0002_977,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,PSIVISSIG0002_978,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,979,PSIVISSIG0002_979,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,980,PSIVISSIG0002_980,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,944,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,981,PSIVISSIG0002_981,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,982,PSIVISSIG0002_982,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,983,PSIVISSIG0002_983,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,984,PSIVISSIG0002_984,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,985,PSIVISSIG0002_985,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,986,PSIVISSIG0002_986,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,987,PSIVISSIG0002_987,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,988,PSIVISSIG0002_988,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,989,PSIVISSIG0002_989,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,990,PSIVISSIG0002_990,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,991,PSIVISSIG0002_991,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,PSIVISSIG0002_992,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1076,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,993,PSIVISSIG0002_993,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,994,PSIVISSIG0002_994,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,995,PSIVISSIG0002_995,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,996,PSIVISSIG0002_996,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1056,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,997,PSIVISSIG0002_997,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,991,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,PSIVISSIG0002_998,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,999,PSIVISSIG0002_999,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,389,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1000,PSIVISSIG0002_1000,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1490,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,PSIVISSIG0002_1001,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1002,PSIVISSIG0002_1002,32,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,537,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,PSIVISSIG0002_1003,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1004,PSIVISSIG0002_1004,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1005,PSIVISSIG0002_1005,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1006,PSIVISSIG0002_1006,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1007,PSIVISSIG0002_1007,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,303,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1008,PSIVISSIG0002_1008,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1009,PSIVISSIG0002_1009,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1010,PSIVISSIG0002_1010,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,PSIVISSIG0002_1011,23,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1012,PSIVISSIG0002_1012,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1013,PSIVISSIG0002_1013,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1014,PSIVISSIG0002_1014,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1015,PSIVISSIG0002_1015,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1016,PSIVISSIG0002_1016,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1521,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1017,PSIVISSIG0002_1017,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1018,PSIVISSIG0002_1018,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1019,PSIVISSIG0002_1019,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,274,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1020,PSIVISSIG0002_1020,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1021,PSIVISSIG0002_1021,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1022,PSIVISSIG0002_1022,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1023,PSIVISSIG0002_1023,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,925,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1024,PSIVISSIG0002_1024,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,573,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1025,PSIVISSIG0002_1025,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1026,PSIVISSIG0002_1026,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,495,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1027,PSIVISSIG0002_1027,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,472,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1028,PSIVISSIG0002_1028,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1029,PSIVISSIG0002_1029,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1030,PSIVISSIG0002_1030,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1031,PSIVISSIG0002_1031,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1032,PSIVISSIG0002_1032,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1033,PSIVISSIG0002_1033,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1034,PSIVISSIG0002_1034,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,672,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1035,PSIVISSIG0002_1035,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1036,PSIVISSIG0002_1036,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1037,PSIVISSIG0002_1037,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1038,PSIVISSIG0002_1038,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1039,PSIVISSIG0002_1039,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1217,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1040,PSIVISSIG0002_1040,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1041,PSIVISSIG0002_1041,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1042,PSIVISSIG0002_1042,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1043,PSIVISSIG0002_1043,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1044,PSIVISSIG0002_1044,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1045,PSIVISSIG0002_1045,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1046,PSIVISSIG0002_1046,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1047,PSIVISSIG0002_1047,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1048,PSIVISSIG0002_1048,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1049,PSIVISSIG0002_1049,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,822,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1050,PSIVISSIG0002_1050,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1047,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1051,PSIVISSIG0002_1051,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1052,PSIVISSIG0002_1052,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1053,PSIVISSIG0002_1053,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,105,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1054,PSIVISSIG0002_1054,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1055,PSIVISSIG0002_1055,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1056,PSIVISSIG0002_1056,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1057,PSIVISSIG0002_1057,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1058,PSIVISSIG0002_1058,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1059,PSIVISSIG0002_1059,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1060,PSIVISSIG0002_1060,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,333,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1061,PSIVISSIG0002_1061,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,604,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1062,PSIVISSIG0002_1062,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1063,PSIVISSIG0002_1063,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,92,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1064,PSIVISSIG0002_1064,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1065,PSIVISSIG0002_1065,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,170,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1066,PSIVISSIG0002_1066,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1067,PSIVISSIG0002_1067,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1068,PSIVISSIG0002_1068,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,879,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1069,PSIVISSIG0002_1069,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,227,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1070,PSIVISSIG0002_1070,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1071,PSIVISSIG0002_1071,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,880,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1072,PSIVISSIG0002_1072,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1073,PSIVISSIG0002_1073,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,211,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1074,PSIVISSIG0002_1074,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1750,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1075,PSIVISSIG0002_1075,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1076,PSIVISSIG0002_1076,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1077,PSIVISSIG0002_1077,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,897,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1078,PSIVISSIG0002_1078,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1079,PSIVISSIG0002_1079,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1080,PSIVISSIG0002_1080,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1776,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1081,PSIVISSIG0002_1081,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,622,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1082,PSIVISSIG0002_1082,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1436,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1083,PSIVISSIG0002_1083,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1084,PSIVISSIG0002_1084,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1085,PSIVISSIG0002_1085,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1086,PSIVISSIG0002_1086,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1597,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1087,PSIVISSIG0002_1087,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1088,PSIVISSIG0002_1088,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1089,PSIVISSIG0002_1089,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
